Apollomics
Tuesday, June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 2
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Company Website:
http://www.apollomicsinc.com
Lead Product in Development:
Vebreltinib
Exchange
Nasdaq
Ticker
APLM
Company HQ City
Foster City
Company HQ State
California
Company HQ Country
United States
CEO/Top Company Official
Guo Liang Yu
Development Phase of Primary Product
Phase II
Speakers